Product Code: 596200534
T2DM drug manufacturers: Compare your brand to 7 major competitors
How loyal are doctors to your Type 2 Diabetes Mellitus (T2DM) brand? How many other brands do they recommend? Which ones? What can you do to set your brand apart and win more market share?
Get the answers in FirstView's NPS+ Type 2 Diabetes Mellitus report.
Based on your brand's net promoter score (NPS), the report gives you an in-depth look at brand loyalty for T2DM treatments, and how it affects your market share. You'll learn who your closest competitors are, how doctors perceive your brand, and which messages drive doctor recommendations.
Find out How Doctors View T2DM Drug Brands
- Byetta : Byetta's market share among Promoters is similar to Onglyza's and Farxiga's. Which of the three stands to gain the most by winning over Detractors?
- Forxiga : Could lack of first-hand experience with Farxiga be preventing its Detractors from recommending it more?
- Invokana : Invokana has the lowest market share among Promoters. How much does it stand to gain by winning over Detractors?
- Januvia : Does Januvia or Lantus stand to gain more market share by converting its Promoters into Detractors?
- Lantus : Does cost effectiveness drive more recommendations for Lantus or Levemir?
- Levemir : What key difference between Levemir and Lantus do brand DNA findings highlight?
- Onglyza : Onglyza's brand DNA reveals concern about a serious potential complication. What is it?
- Victoza : Which other brand do over 86% of Victoza Promoters also promote?
Get answers to key questions about brand loyalty
NPS+ Type 2 Diabetes Mellitus report explores key issues affecting brand loyalty for T2DM drug manufacturers. You'll learn:
- How satisfied the T2DM market is.
- How loyal doctors are to your brand.
- How many other brands are promoted by your Promoters.
- Which other brands are promoted by your Promoters and by your Detractors.
- How much market share your brand has among Promoters and Detractors.
- How much market share you would gain if your Detractors became Promoters.
- Which messages Promoters, Passives and Detractors associate with your brand.
- Your brand DNA: what promoters and detractors really think of your brand-in their own words.
Results are presented in clear, intuitive KPIs that highlight areas where your brand can improve, and make it easy to see what your next steps are.
- Only three of the surveyed brands have a positive NPS : And the leading brand's score is more than three times that of its nearest competitor.
- Satisfaction is moderate, but lower than in the US : In the EU5 countries, nearly 15% fewer doctors are satisfied with available T2DM brands than in the US.
- Exclusivity is low : While doctors are relatively satisfied with available treatments, less than 15% of them promote one brand exclusively.
- Lack of familiarity is a concern for newer brands : Many brand Detractors state that they don't use, or don't know enough about newer T2DM brands.
- Cost is a moderate-to-high concern : For all but 2 of the brands surveyed, cost is a medium-to-strong driver of doctor recommendations, but not as important as key clinical attributes.
- One brand has the potential for massive market share gain : 2 to 6 times as much as any other surveyed brand if it can turn its Detractors into Promoters.
- Impact of promotional messages limited for some brands : For many of the surveyed brands, few messages are associated with more than 50% of Promoters.
- Two brands are the top choices among Promoters : Promoters of most surveyed brands also promote two other brands more than they promote any others.
A Report Based on Expert Knowledge
We surveyed 150 EU5 (France, Italy, Germany, Spain, UK) Physicians -a mix of Endocrinologists and General Practitioners chosen from the largest community of validated physicians in the world. The same community that pharma market researchers trust for reliable, fast intelligence.
We conducted the survey between November 18th and 24th, 2015.
- Byetta (exenatide; AstraZeneca)
- Forxiga (dapagliflozin; AstraZeneca)
- Invokana (canagliflozin; Janssen)
- Januvia (sitagliptin; Merck Sharp & Dohme)
- Lantus (insulin glargine; Sanofi)
- Levemir (insulin detemir; Novo Nordisk)
- Onglyza (saxagliptin; AstraZeneca)
- Victoza (liraglutide; Novo Nordisk)
What is Net Promoter® Score?
NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.
How does NPS work?
NPS measures overall brand satisfaction and loyalty by asking one simple question:
"How likely are you to recommend this brand to a colleague?"
Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)-are used to classify respondents into 3 categories:
- Detractors are those who answer 0 - 6.
- Passives are those who answer 7 - 8.
- Promoters are those who answer 9 - 10.
How is NPS calculated?
The percentage of detractors - the percentage of promoters = NPS.
For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.
NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.
What is FirstView NPS+?
NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.
Each NPS+ report examines doctors' relationships with the brands used to treat a major disease area-measuring brand loyalty and showing you how it affects your market share . NPS+ also examines "brand DNA", revealing in doctors' own words what brands mean to them.
Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.